India, June 8 -- Monday, Standard BioTools Inc. (LAB) announced an agreement with Treeline Biosciences, Inc., a clinical-stage biopharma company, to combine in an all-stock transaction.
The transaction values Standard BioTools at net cash delivered at closing, plus $10 million, which is estimated to be $460 million. At the closing of the deal, pre-merger Standard BioTools stockholders are expected to own approximately 16% of the combined company, whereas pre-merger Treeline stockholders are expected to own the remaining.
Upon completion of the deal, the combined company will trade on the Nasdaq under the ticker symbol "TRLN" and operate under the name Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein de...